- Prev. close
- ₩241,000
- Volume
- 456.6K
- Market cap
- ₩5.7T
Stock and sector context
Healthcareoutflow- Sector comparison
- Sam Chun Dang Pharm changed 0.00%. The 13 covered Healthcare stocks in Korean averaged -0.82%, with estimated sector flow of outflow.
- Variables to watch
- Drug approvals and trial resultsDrug pricing policyUS interest ratesUSD/KRW
- Risks to check
- -80% below the high, the downtrend may continue
- Clinical trial failure
- Drug pricing pressure
This compares price changes among covered stocks in the same market. It does not establish why prices moved. Variables and risks are sector reference lists.
Why a candidate
Match 55/100The match score marks how many conditions overlap on a 0 to 100 scale: the 52-week range, valuation metrics, price change and volume. It is not a probability of rising or a forecast return.
Today's read
Sam Chun Dang Pharm scores 55 out of 100 on today's InverseOne match ranking, 18 of 60 in the Korean large-cap universe. The gap to its 52-week high is 412%. Today's move of 0.00% came with money flowing in, alongside the Healthcare sector. Scores are estimates built from price and volume, a starting point for research rather than a trading signal.
Data basis: 2026-10-07 close, 10-12 00:16 KST updated, For reference only, not advice
Same-sector stocks, Healthcare
Lending balance
Building1,567,262 sh
KRW 0.38T
New 116,183 sh, Returned 66,783 sh
Shares borrowed through securities lending that have not yet been returned. Borrowed shares are often sold afterwards, so the balance is used as a reference for pending sell pressure.
As of 2026-10-08, FSC stock lending data
Talk about this stock
Today's talking points
- It sits low in its 52-week range (11).
- Borrowed shares are piling up. The lending balance is growing.
- It is 412% below its 52-week high.
Three months out, which way do you see it?
Nobody has answered yet. Sign in to be the first.
These are answers picked by members, not investment advice.
These figures are reference estimates built from price and volume: a starting point for narrowing down ideas, not a buy or sell signal.